Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12335640 | 1.00 | CHRM2 (0.34) | CHRM2GSRRNPEPCPB2NFKB1 | |
| SCHEMBL1915006 | 0.78 | ADH1B (0.44) | — | |
| SCHEMBL26437943 | 0.77 | TSHR (0.48) | — | |
| SCHEMBL16592070 | 0.77 | TSHR (0.48) | — | |
| SCHEMBL6653857 | 0.77 | TSHR (0.48) | — | |
| SCHEMBL20411714 | 0.75 | ADH1B (0.45) | — | |
| SCHEMBL18572798 | 0.75 | ADH1B (0.45) | — | |
| SCHEMBL20767759 | 0.74 | — | — | |
| SCHEMBL26019039 | 0.74 | EPHX1 (0.37) | — | |
| SCHEMBL26541492 | 0.74 | CYP2C19 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| US-10954269-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-03-23 | — | — | US | disclosed |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2020-04-23 | — | — | US | disclosed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10227379-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20180244742-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2018-08-30 | — | — | US | disclosed |
| US-10000542-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2018-06-19 | — | — | US | disclosed |
| CN-104519902-B | Double acylated GLP-1 derivatives | 诺和诺德股份有限公司 | 2017-10-27 | — | — | CN | disclosed |
| CN-104411322-B | Double acylated GLP-1 derivatives | 诺和诺德股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104519902-A | Double-acylated GLP-1 derivatives | NOVO NORDISK AS | 2015-04-15 | — | — | CN | disclosed |
| WO-2015040235-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-03-26 | — | — | WO | disclosed |
| EP-2846823-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| EP-2846824-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| CN-104411322-A | Double acylated GLP-1 derivatives | NOVO NORDISK AS | 2015-03-11 | — | — | CN | disclosed |
| US-8802773-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2013167455-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013167454-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8426554-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2013-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | CHRM2 1524/4885GSR 1922/4885RNPEP 3377/4885 |
| US-20180244742-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | CHRM2 1547/4885GSR 2008/4885RNPEP 3398/4885 |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | CHRM2 4168/4885GSR 2611/4885RNPEP 85/4885 |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | CHRM2 1866/4885GSR 1869/4885RNPEP 11/4885 |
| US-10954269-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | CHRM2 4168/4885GSR 2611/4885RNPEP 85/4885 |
| US-10000542-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | CHRM2 1524/4885GSR 1922/4885RNPEP 3377/4885 |
| US-10227379-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | CHRM2 4168/4885GSR 2611/4885RNPEP 85/4885 |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | CHRM2 1524/4885GSR 1922/4885RNPEP 3377/4885 |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | CHRM2 1524/4885GSR 1922/4885RNPEP 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.